Key Details
Price
$3.28Annual ROE
-30.86%Beta
1.02Events Calendar
Next earnings date:
Feb 27, 2025Recent quarterly earnings:
Nov 7, 2024Recent annual earnings:
Feb 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
We have put together a list of the 15 healthcare stocks that are performing exceptionally well in 2025. In this article, we will examine how Agilon Health Inc (NYSE:AGL) compares to other healthcare stocks. The healthcare industry is recovering in 2025 after two years of poor performance.
AGL, ASHTY and CCOZY have been added to the Zacks Rank #5 (Strong Sell) List on January 28, 2024.
WMS, AGL and EADSY have been added to the Zacks Rank #5 (Strong Sell) List on January 24, 2025.
AGL, AMPH and CR have been added to the Zacks Rank #24 (Strong Sell) List on December 31, 2024.
AGL, BKGFY and BERY have been added to the Zacks Rank #5 (Strong Sell) List on December 13, 2024.
ATI, ARLP and AGL have been added to the Zacks Rank #5 (Strong Sell) List on December 4, 2024.
ATI, ATS and AGL have been added to the Zacks Rank #5 (Strong Sell) List on December 2, 2024.
agilon health, inc. (NYSE:AGL ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Leland Thomas - Senior Manager-Investor Relations Steven Sell - Chief Executive Officer Jeffrey Schwaneke - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Justin Lake - Wolfe Research Adam Ron - Bank of America George Hill - Deutsche Bank Sameer Patel - Evercore Ryan Langston - TD Cowen Stephen Baxter - Wells Fargo Andrew Mok - Barclays Jack Slevin - Jefferies Michael Ha - Baird Thomas Keller - RBC Daniel Grosslight - Citi Operator Good afternoon and thank you for joining the agilon health Third Quarter 2024 Earnings Conference Call.
I initially rated agilon health, inc. as a “hold” due to its volatile financial results and uncertain future, but recent developments necessitate a downgrade to 'sell'. The company's stock plummeted 60.1% since my last article, driven by disappointing Q3 results and reduced guidance, despite revenue growth. Rising medical costs and expansion expenses have severely impacted profitability, with a significant increase in net loss and negative EBITDA.
Agilon Health (AGL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.06 per share a year ago.
FAQ
- What is the ticker symbol for agilon health?
- Does agilon health pay dividends?
- What sector is agilon health in?
- What industry is agilon health in?
- What country is agilon health based in?
- When did agilon health go public?
- Is agilon health in the S&P 500?
- Is agilon health in the NASDAQ 100?
- Is agilon health in the Dow Jones?
- When was agilon health's last earnings report?
- When does agilon health report earnings?
- Should I buy agilon health stock now?